<DOC>
	<DOCNO>NCT01422512</DOCNO>
	<brief_summary>This study evaluate safety immunogenicity surface , antigen , inactivate , influenza vaccine produce mammalian cell culture administer adult elderly subject .</brief_summary>
	<brief_title>Safety Immunogenicity One Dose Surface , Antigen , Inactivated , Influenza Vaccine Produced Mammalian Cell Culture Administered Adult Elderly Subjects</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Males female volunteer 18 year age old , mentally competent , willing able give write informed consent prior study entry 2 . Individuals able comply study requirement 3 . Individuals good health determine outcome medical history , physical examination clinical judgment investigator 1 . Individuals behavioral cognitive impairment psychiatric disease , opinion investigator , may interfere subject 's ability participate study 2 . Individuals serious chronic acute disease include limited : Medically significant Cancer , Medically significant advance congestive heart failure ( ie . NYHA class III IV ) , Chronic obstructive pulmonary disease ( COPD ) ; Autoimmune disease ( include rheumatoid arthritis , except Hashimoto 's thyroiditis clinically stable ≥ 5 year ) ; Diabetes mellitus type I/II ; Advanced arteriosclerotic disease ; History underlie medical condition major congenital abnormality require surgery , chronic treatment , associate developmental delay ( e.g. , Down 's syndrome ) ; Acute progressive hepatic disease ; Acute progressive renal disease ; Severe neurological psychiatric disorder ; Severe asthma 3 . Individuals history anaphylactic reaction and/or serious allergic reaction follow vaccination 4 . Individuals know suspected impairment/alteration immune function result , example , : receipt immunosuppressive therapy ( parenteral oral corticosteroid cancer chemotherapy/radiotherapy ) within past 60 day full length study ; receipt immunostimulants ; receipt parenteral immunoglobulin preparation , blood product and/or plasma derivates within past 3 month full length study ; suspect know HIV infection HIVrelated disease 5 . Individuals know suspected history drug alcohol abuse 6 . Individuals bleed diathesis condition associate prolonged bleeding time investigator 's opinion would interfere safety subject 7 . Female pregnant nursing ( breastfeed ) mother females childbearing potential planning use acceptable birth control measure , whole duration study 8 . Individuals history illness , opinion investigator , might interfere result study pose additional risk subject due participation study 9 . Individuals within past 6 month seasonal pandemic laboratory confirm influenza disease 10 . Individuals receive seasonal pandemic influenza vaccine ; 11 . Individuals acute chronic infection require systemic antibiotic treatment antiviral therapy within last 7 day 12 . Individuals experience fever ( i.e. , axillary temperature ≥ 38°C ) within last 3 day intend study vaccination 13 . Individuals participate another clinical trial 14 . Individuals ever receive blood , blood product and/or plasma derivative parenteral immunoglobulin preparation past 12 week full length study 15 . Individuals part study personnel close family member conduct study 16 . BMI &gt; 35 kg/m2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>seasonal influenza</keyword>
	<keyword>vaccine</keyword>
</DOC>